Literature DB >> 15741265

Germline homozygous mutations at codon 804 in the RET protooncogene in medullary thyroid carcinoma/multiple endocrine neoplasia type 2A patients.

F Lesueur1, A Cebrian, A Cranston, J Leyland, T M Faid, M R Clements, M Robledo, J Whittaker, B A J Ponder.   

Abstract

The effect of mutations at codon 804 in the RET protooncogene is disputed. Some studies have suggested that the V804L mutation causes the low penetrance multiple endocrine neoplasia type 2 syndrome, with late onset and relatively indolent course, whereas others have reported that V804L and V804M have an aggressive potential. In this paper, we report three apparently unrelated medullary thyroid carcinoma cases homozygous for these mutations. To clarify the phenotypic heterogeneity associated with these mutations, we compare the clinical data and age of diagnosis among these three homozygous patients, six other heterozygous cases from the same populations, and other homozygous and heterozygous subjects reported previously. The data are consistent with a model in which codon 804 mutations have low penetrance, the developing of medullary thyroid carcinoma being associated with a second germline or somatic mutation. The activity and (in the case of somatic mutations) timing of these other genetic alterations in the RET gene may explain the wide clinical variability associated with germline mutations at codon 804.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15741265     DOI: 10.1210/jc.2004-1622

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Identification and characterization of two novel germline RET variants associated with medullary thyroid carcinoma.

Authors:  A L Silva; F Carmo; M M Moura; R Domingues; C Espadinha; V Leite; B Cavaco; M J Bugalho
Journal:  Endocrine       Date:  2015-03-01       Impact factor: 3.633

Review 2.  RET signaling in endocrine tumors: delving deeper into molecular mechanisms.

Authors:  Andrea Z Lai; Taranjit S Gujral; Lois M Mulligan
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

3.  How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer.

Authors:  Hugo Prazeres; Joana Torres; Fernando Rodrigues; Joana P Couto; João Vinagre; Manuel Sobrinho-Simões; Paula Soares
Journal:  J Thyroid Res       Date:  2011-06-23

4.  The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression/penetrance studies.

Authors:  Carla Colombo; Emanuela Minna; Maria Grazia Rizzetti; Paola Romeo; Daniele Lecis; Luca Persani; Piera Mondellini; Marco A Pierotti; Angela Greco; Laura Fugazzola; Maria Grazia Borrello
Journal:  Orphanet J Rare Dis       Date:  2015-03-01       Impact factor: 4.123

5.  p.Val804Met, the Most Frequent Pathogenic Mutation in RET, Confers a Very Low Lifetime Risk of Medullary Thyroid Cancer.

Authors:  Chey Loveday; Katherine Josephs; Daniel Chubb; Adam Gunning; Louise Izatt; Marc Tischkowitz; Sian Ellard; Clare Turnbull
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

6.  Identification of a secondary RET mutation in a pediatric patient with relapsed acute myeloid leukemia leads to the diagnosis and treatment of asymptomatic metastatic medullary thyroid cancer in a parent: a case for sequencing the germline.

Authors:  Danielle M Pendrick; Jennifer A Oberg; Susan J Hsiao; Wendy K Chung; Carrie Koval; Anthony Sireci; Jennifer H Kuo; Prakash Satwani; Chana L Glasser; Maria Luisa Sulis; Mahesh M Mansukhani; Julia L Glade Bender
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-04-01

7.  Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients.

Authors:  Jie Yang; Hefei Li; Ben Li; Wei Li; Qiang Guo; Ling Hu; Zizheng Song; Bin Zhou
Journal:  Front Oncol       Date:  2021-04-07       Impact factor: 6.244

8.  Unexpected Pathogenic RET p.V804M Variant Leads to the Clinical Diagnosis and Management of Medullary Thyroid Carcinoma.

Authors:  Arezou A Ghazani; Katelyn M Breen; Meaghan Dwan; Justine A Barletta; Donna R Vatnick; Samantha M Stokes; Caroline Block; Gerard M Doherty; Aviva Y Cohn; Ellen Marqusee; Judy E Garber; Huma Q Rana
Journal:  Am J Case Rep       Date:  2020-12-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.